These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 6675504)

  • 1. [Heparin and chemically related compounds. Study in experimental thrombosis].
    Vairel EG; Brouty-Boyé H; Toulemonde F; Doutremepuich C
    Ann Pharm Fr; 1983; 41(5):421-5. PubMed ID: 6675504
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lysis of fresh experimental thrombi under the action of a secondary adrenaline-heparin-fibrinogen complex].
    Liapina LA; Zhitnikova ES; Kudriashov BA
    Farmakol Toksikol; 1978; 41(1):82-5. PubMed ID: 624394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combined use of terrilytin, sodium salicylate and heparin for the purpose of regulating hemostasis].
    Mamedov IaD; Reĭsh AV
    Probl Gematol Pereliv Krovi; 1981 May; 26(5):52-5. PubMed ID: 6166936
    [No Abstract]   [Full Text] [Related]  

  • 4. [Products of fibrinolysis in experimental pulmonary embolism. Effect of heparin in its production].
    Patiño R; De La Serna JL; Mateo-Martín I; Tamayo F; Durán Sacristán M
    Rev Esp Cardiol; 1976; 29(3):223-6. PubMed ID: 948680
    [No Abstract]   [Full Text] [Related]  

  • 5. Heparin compromises streptokinase-induced arterial patency in rabbits.
    Vlasin M; Rak J; Weitz JI; Peng L; Gumulec J; Johnston M; Klement P
    Thromb Res; 2005; 115(5):427-34. PubMed ID: 15733977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of the indirect fibrinolytic activity of heparins and similar compounds in the prevention of thrombosis].
    Vairel EG; Brouty-Boyé H; Toulemonde F; Doutremepuich C
    Ann Pharm Fr; 1983; 41(4):339-53. PubMed ID: 6670818
    [No Abstract]   [Full Text] [Related]  

  • 7. [On activation of fibrinolysis in vitro and in vivo by nicotinic acid, heparin and their mixtures].
    Goossens N
    Med Welt; 1967 Apr; 14():899-903. PubMed ID: 4869469
    [No Abstract]   [Full Text] [Related]  

  • 8. [Heparin and fibrinolysis inhibitors].
    Villaverde CA; Badimón L; Vidal M; Badimón JJ; Valdecasas FG
    Arch Farmacol Toxicol; 1981 Apr; 7(1):97-100. PubMed ID: 7325724
    [No Abstract]   [Full Text] [Related]  

  • 9. [Formation of the heparin-calcium complex].
    Kudriashov BA; Liapina LA
    Vopr Med Khim; 1982; 28(5):112-5. PubMed ID: 7179827
    [No Abstract]   [Full Text] [Related]  

  • 10. [Heparin-urea complex and its biological properties].
    Liapina LA; Kudriashov BA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1975; (10):46-9. PubMed ID: 1203401
    [No Abstract]   [Full Text] [Related]  

  • 11. Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients.
    Bacher P; Horst B; Breyer HG; Hoppensteadt DA; Walenga JM; Fareed J
    Semin Thromb Hemost; 1993; 19 Suppl 1():73-8. PubMed ID: 8395735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of the joint administration of heparin and chitosan sulfate ether on hemostatic function].
    Drozd NN; Makarov VA; Bashkov GV; Gal'braĭkh LS; Vikhoreva GA; Gorbacheva IN
    Eksp Klin Farmakol; 1996; 59(1):30-3. PubMed ID: 8704629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological study of the streptokinase preparation, avelizin].
    Markwardt F; Klöcking HP
    Farmakol Toksikol; 1980; 43(6):671-4. PubMed ID: 7450003
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effect of heparin on fibrinolysis, complement, and kinin generation systems (author's transl)].
    Nakagawa M; Kitani T
    Rinsho Ketsueki; 1981 Jul; 22(7):1016-22. PubMed ID: 7328761
    [No Abstract]   [Full Text] [Related]  

  • 15. [Influence of ellagic acid and heparin on coagulation, fibrinolysis and metastasis in traumatized animals (author's transl)].
    Agostino D; Agostino N
    Sangre (Barc); 1980; 25(6):989-98. PubMed ID: 7221832
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits.
    Friederich PW; Levi M; Biemond BJ; Charlton P; Templeton D; van Zonneveld AJ; Bevan P; Pannekoek H; ten Cate JW
    Circulation; 1997 Aug; 96(3):916-21. PubMed ID: 9264501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of sodium heparin on activated fibrinolysis in the rat in vivo].
    Badimón L; Villaverde C; Badimón JJ; Vidal M; Valdecasas FG
    Arch Farmacol Toxicol; 1981 Apr; 7(1):105-8. PubMed ID: 7325697
    [No Abstract]   [Full Text] [Related]  

  • 18. Low molecular weight heparin: laboratory properties and clinical evaluation. A review.
    Hirsh J; Levine MN
    Eur J Surg Suppl; 1994; (571):9-22. PubMed ID: 7519092
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative study of the duration of action of heparin--thromboplastin complex in the bodies of animals maintained on natural and atherogenic diets].
    Liapina LA; Bazaz'ian GG
    Vopr Med Khim; 1981; 27(1):115-20. PubMed ID: 7467198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of nonachlazin, riboxin and isoptin on the blood coagulation system and the anticoagulant effect of heparin].
    Shevchenko LV; Ovchinnikova LK; Zolotukhin SI
    Farmakol Toksikol; 1980; 43(4):389-95. PubMed ID: 7439373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.